Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020198678 - PRIMING WITH TARGETED ACTIVATED T CELLS CAN ENHANCE CHEMO RESPONSIVENESS OF CANCER CELLS

Publication Number WO/2020/198678
Publication Date 01.10.2020
International Application No. PCT/US2020/025461
International Filing Date 27.03.2020
IPC
A61K 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants
  • UNIVERSITY OF VIRGINIA PATENT FOUNDATION [US]/[US]
Inventors
  • LUM, Lawrence, G.
  • THAKUR, Archana
Agents
  • TAYLOR, Arles, A., Jr.
Priority Data
62/824,73327.03.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PRIMING WITH TARGETED ACTIVATED T CELLS CAN ENHANCE CHEMO RESPONSIVENESS OF CANCER CELLS
(FR) UNE PROVOCATION PAR DES LYMPHOCYTES T ACTIVÉS CIBLÉS PEUT AMÉLIORER LA SENSIBILITÉ À LA CHIMIOTHÉRAPIE DE CELLULES CANCÉREUSES
Abstract
(EN)
Methods and compositions for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a targeted activated T cell, such as a bispecific antibody armed activated T cell (BAT), alone or in combination with an effective amount or a subtherapeutic amount of an additional therapeutic agent, wherein the targeted activated T cell selectively binds a cell of the cancer in the subject.
(FR)
L'invention concerne des procédés et des compositions pour le traitement du cancer chez un sujet en ayant besoin, comprenant l'administration au sujet d'une quantité efficace d'une cellule T activée ciblée, telle qu'une cellule T activée armée d'un anticorps bispécifique (BAT), seule ou en combinaison avec une quantité efficace ou une quantité inférieure à la dose thérapeutique d'un agent thérapeutique supplémentaire, la cellule T activée ciblée se liant sélectivement à une cellule du cancer chez le sujet.
Latest bibliographic data on file with the International Bureau